🟢 Eupraxia Pharmaceuticals is trading 12% up today in pre-market despite no clear overnight company-specific announcement

Eupraxia Pharmaceuticals is trading 12.43% up at $7.60 after no clear company-specific announcement was identified overnight.

• Recent company news includes August 13, 2026 RESOLVE trial symptom-response data and August 11, 2026 second-quarter results; neither directly explains the August 21 pre-market spike.
• Broader sentiment is modestly positive, with the Nasdaq Composite up 0.78%, though the move remains unusually large relative to market gains.